It appears that FDA's celebrated approval flexibility for rare disease treatments has its limits, especially when efficacy is questioned.
Agency officials issued a "complete response" letter for BioMarin Pharmaceutical Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?